Abstract: According to an aspect of the disclosed embodiments, an apparatus for a vehicle includes a locking plate configured to be coupled to a first shaft of a suspension rod. A housing is configured to be coupled to a second shaft of the suspension rod that moves relative to the first shaft. The housing extends along a first longitudinal axis. A pin is configured to rotate about a second longitudinal axis. A locking mechanism is configured to lock the pin in starting position.

Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof is described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease are also described.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof, are described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia, are also described.

Abstract: Disclosed are methods, systems and devices for implementing built-in self-test (BIST) to be performed by an untrusted party and/or in an unsecure testing environment. In an embodiment, a test access port (TAP) on a device may enable a party to initiate execution of one or more BIST procedures on the device. Additionally, such a TAP may enable loading of encrypted instructions to be executed by one or more processors formed on a device under test.

Abstract: The present invention relates to films comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as ketamine, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such films, and the use of such films in anesthesia, pain management, and the treatment of disease, in particular amnesia, depression and bipolar disorder.

Abstract: The present invention relates to films comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a carrier system comprising (a) a carrier, (b) a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier, and (c) at least one active pharmaceutical ingredient. The present invention further relates to methods for manufacturing such films, and the use of such films in the treatment of a human patient.

Abstract: Disclosed are methods, systems and devices for implementing built-in self-test (BIST) to be performed by an untrusted party and/or in an unsecure testing environment. In an embodiment, a test access port (TAP) on a device may enable a party to initiate execution of one or more BIST procedures on the device. Additionally, such a TAP may enable loading of encrypted instructions to be executed by one or more processors formed on a device under test.

Abstract: According to an aspect of the disclosed embodiments, an apparatus for a vehicle includes a locking plate configured to be coupled to a first shaft of a suspension rod. A housing is configured to be coupled to a second shaft of the suspension rod that moves relative to the first shaft. The housing extends along a first longitudinal axis. A pin is configured to rotate about a second longitudinal axis. A locking mechanism is configured to lock the pin in starting position.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.